← peptides typeshit

Gilead pays nearly $1.3B for PepStar's oral IL-23 receptor peptide for IBD

Gilead takes global rights to the Shanghai biotech's program, led by HCXT-2001, an oral peptide that could compete with injected IBD drugs.

Read at MedCity News

Recap by typeshit. Full story at MedCity News.